BRD2 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-30474
Key Product Details
Validated by
Independent Antibodies, Biological Validation
Species Reactivity
Validated:
Human
Applications
Immunocytochemistry/ Immunofluorescence, Immunoprecipitation, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
0.2 mg/ml
Product Summary for BRD2 Antibody
Immunogen
The immunogen for this product maps to a region between residue 1 and 50 of human bromodomain containing 2 using the numbering given in entry NP_005095.1 (GeneID 6046).
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Scientific Data Images for BRD2 Antibody
Western Blot: BRD2 Antibody [NBP1-30474]
Western Blot: BRD2 Antibody [NBP1-30474] - Detection of human BRD2 by western blot. Samples: Whole cell lysate (50 ug) from HeLa, HEK293T, and Jurkat cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-BRD2 antibody NBP1-30474 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.Immunocytochemistry/ Immunofluorescence: BRD2 Antibody [NBP1-30474]
Immunocytochemistry/Immunofluorescence: BRD2 Antibody [NBP1-30474] - Formaldehyde-fixed asynchronous HeLa cells. Antibody used at a dilution of 1:100 (2ug/ml) .Applications for BRD2 Antibody
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
1:10-1:2000
Immunoprecipitation
2-5 ug/mg lysate
Western Blot
1:2000-1:10000
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
Tris-buffered Saline
Preservative
0.09% Sodium Azide
Concentration
0.2 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C. Do not freeze.
Background: BRD2
BRD2 and the other BET proteins have been implicated in a variety of diseases and pathologies. The BET proteins are known drivers of cancer through mutation and over-expression (1). Recently, in studies examining the role of Type 2 diabetes and obesity in breast cancer progression, the BET proteins have been shown to be critical regulators of metabolism and metastasis and are co-activators for the transcription of genes that encode pro-inflammatory cytokines in immune cells infiltrating the breast cancer microenvironment (1). Accordingly, knockdown of Brd2 in mice protected the animals from developing Type 2 diabetes and stopped the inflammatory response typically elicited by obesity (4). BRD2 is also highly expressed in the brain and the gene has been shown to play a role in juvenile myoclonic epilepsy, a common form of epilepsy that typically reveals itself during adolescence (5). In addition to the brain, BRD2 is highly expressed in the bone marrow and consequently its kinase activity has been shown to increase upon cellular proliferation and is significantly elevated in the peripheral blood lymphocytes of lymphoma patients (2, 3).
Research has been done to better understand protein interactions with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of the novel coronavirus disease 2019 (COVID-19), as possible targets for drug therapies. It was recently described that that the transmembrane envelope protein (E) of SARS-CoV-2 binds to both BRD2 and BRD4, suggesting that bromodomain inhibitors could be a potential drug target (6). More specifically, the bromodomain inhibitors could be relevant regarding the secondary immune-related consequences that arise from SARS-CoV-2 infection (6). Bromodomain inhibitors are currently the focus of multiple clinical trials as a potential therapeutic in cancer and pulmonary arterial hypertension (6).
References
1. Andrieu, G.P., Shafran, J.S., Deeney, J.T., Bharadwaj, K.R., Rangarajan, A., & Denis, G.V. (2018). BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment. J Leukoc Biol. https://doi:10.1002/JLB.5RI0917-380RR
2. BRD2 bromodomain 2 (human), NCBI
3. Taniguchi, Y. (2016). The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. Int J Mol Sci. https://doi:10.3390/ijms17111849
4. Wang, F., Deeney, J.T., & Denis, G.V. (2013). Brd2 gene disruption causes "metabolically healthy" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes. Vitam Horm. https://doi:10.1016/B978-0-12-407766-9.00003-1
5. Gilsoul, M., Grisar, T., Delgado-Escueta, A.V., de Nijs, L., & Lakaye, B. (2019). Subtle Brain Developmental Abnormalities in the Pathogenesis of Juvenile Myoclonic Epilepsy. Front Cell Neurosci. https://doi:10.3389/fncel.2019.00433
6. Harrison, C. (2020). Drug researchers pursue new lines of attack against COVID-19. Nat Biotechnol. https://doi.org/10.1038/d41587-020-00013-z
Long Name
Bromodomain Containing 2
Alternate Names
FSRG1, RING3, RNF3
Gene Symbol
BRD2
Additional BRD2 Products
Product Documents for BRD2 Antibody
Product Specific Notices for BRD2 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...